JP Morgan Chase
AUTL

JP Morgan Chase’s Autolus Therapeutics AUTL Stock Holding History

JP Morgan Chase’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
913,239
-22,164
-2% -$34.8K ﹤0.01% 4395
2026
Q1 		$1.19M Sell
935,403
-43,872
-4% -$66.6K ﹤0.01% 4490
2025
Q4 		$1.95M Buy
979,275
+76,207
+8% +$117K ﹤0.01% 4089
2025
Q3 		$1.47M Sell
903,068
-11,675
-1% -$22.8K ﹤0.01% 4308
2025
Q2 		$2.09M Sell
914,743
-495,361
-35% -$819K ﹤0.01% 3885
2025
Q1 		$2.19M Buy
1,410,104
+338,571
+32% +$687K ﹤0.01% 3804
2024
Q4 		$2.52M Sell
1,071,533
-213,175
-17% -$721K ﹤0.01% 3971
2024
Q3 		$4.66M Buy
1,284,708
+761,008
+145% +$3.03M ﹤0.01% 3269
2024
Q2 		$1.82M Buy
523,700
+394,791
+306% +$1.7M ﹤0.01% 3865
2024
Q1 		$822K Buy
128,909
+101,476
+370% +$633K ﹤0.01% 4482
2023
Q4 		$177K Buy
27,433
+27,327
+25,780% +$104K ﹤0.01% 5456
2023
Q3 		$247 Sell
106
-1,693
-94% -$4.82K ﹤0.01% 6814
2023
Q2 		$4.28K Sell
1,799
-439,226
-100% -$1.04M ﹤0.01% 6201
2023
Q1 		$811K Sell
441,025
-52,484
-11% -$103K ﹤0.01% 4186
2022
Q4 		$938K Buy
493,509
+50,959
+12% +$129K ﹤0.01% 4089
2022
Q3 		$947K Sell
442,550
-183,969
-29% -$545K ﹤0.01% 4043
2022
Q2 		$1.77M Sell
626,519
-173,039
-22% -$527K ﹤0.01% 3647
2022
Q1 		$3.33M Sell
799,558
-51,986
-6% -$219K ﹤0.01% 3342
2021
Q4 		$4.42M Sell
851,544
-499,811
-37% -$3M ﹤0.01% 3166
2021
Q3 		$8.85M Buy
1,351,355
+600,391
+80% +$3.79M ﹤0.01% 2492
2021
Q2 		$4.99M Buy
750,964
+196,595
+35% +$1.22M ﹤0.01% 3049
2021
Q1 		$3.18M Buy
554,369
+300,109
+118% +$2.22M ﹤0.01% 3353
2020
Q4 		$2.27M Buy
254,260
+75,626
+42% +$806K ﹤0.01% 3387
2020
Q3 		$2.14M Buy
178,634
+37,879
+27% +$549K ﹤0.01% 3175
2020
Q2 		$2.26M Buy
140,755
+39,308
+39% +$436K ﹤0.01% 3030
2020
Q1 		$608K Buy
101,447
+63,234
+165% +$584K ﹤0.01% 3725
2019
Q4 		$504K Buy
+38,213
New +$500K ﹤0.01% 4234

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase's AUTL Position: Q2 2026 in Review

JP Morgan Chase reduced its Autolus Therapeutics (AUTL) stake by 2.4% in Q2 2026, selling an estimated $34.8K and leaving 913,239 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

JP Morgan Chase first reported a position in AUTL in Q4 2019 and has held it in 27 quarters since. The position peaked at $8.85M in Q3 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • JP Morgan Chase held 913,239 shares of Autolus Therapeutics worth $1.51M as of Q2 2026.
  • JP Morgan Chase sold 22,164 Autolus Therapeutics shares in Q2 2026, an estimated $34.8K.
  • Autolus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4395 holding.
  • JP Morgan Chase first reported a position in Autolus Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Autolus Therapeutics position peaked at $8.85M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.